Security Investigation

Invivyd, Inc. (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (NasdaqGM: ADGI)

9 Days left to seek lead plaintiff status.

Company Name:Invivyd, Inc. f/k/a Adagio Therapeutics, Inc.
Stock Symbol:NasdaqGM: IVVD - NasdaqGM: ADGI
Court:District of Massachusetts
Class Period Start:11/29/2021
Class Period End (inclusive):12/14/2021
Filing Deadline:04/03/2023

Contact a Lawyer Now

(877) 515-1850

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 3, 2023 to file lead plaintiff applications in a securities class action lawsuit against Invivyd, Inc. (the “Company”) (NasdaqGM: IVVD) f/k/a Adagio Therapeutics, Inc. (“Adagio”) (NasdaqGM: ADGI).

Invivyd and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. 

On December 14, 2021, the Company (then named Adagio) disclosed that in vitro test results for ADG20, its lead product candidate against the COVID-19 Omicron variant, revealed that it was 300 times less effective at neutralizing Omicron than it was against the other variants, despite assuring investors of the efficacy against Omicron only a few weeks prior.

On this news, shares of Adagio plummeted nearly 80%, from $34.26 per share on December 13, 2021, to $7.26 per share when the market closed on December 14, 2021.

If you purchased shares of Invivyd and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (lewis.kahn@ksfcounsel.com), or fill out the form on this page.

The case is Brill v. Invivyd, Inc., No. 23-cv-10254.

Click here to read the first filed complaint.